Author: Customer Service

Median overall survival of 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer patients treated with azenosertib monotherapy  Data to be presented as a rapid oral presentation at ESMO Congress 2026 on October 23, 2026SAN DIEGO, Oct. 18, 2026 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that overall survival (OS) data from an interim analysis of the DENALI Part 1b study (GOG-3066) have been published in the abstract for the upcoming rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026. The published abstract reports results for OS, a secondary endpoint of...

Presentations to cover updates across Eikon’s clinical pipeline including: Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and histology-appropriate chemotherapy in stage 4 non-small cell lung cancer (NSCLC) Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumors Initial data from a Phase 1/2 study of EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancer Initial results from an ongoing Phase 1/2 study of EIK1004, a highly selective CNS-penetrant PARP1 inhibitor in advanced solid malignancies Preliminary safety, tolerability and pharmacokinetic data for EIK1005, a Werner (WRN) helicase...

WATERTOWN, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will host a corporate webcast to discuss topline results from the APOLLO Phase 3 trial of bitopertin in EPP. The webcast will be held on Monday, October 19, 2026 at 8:00 a.m. ET. Webcast Information Please register for the event on the Events and Presentations page of Disc’s website at https://ir.discmedicine.com. A replay of the webcast will be made available on the website following the call. About Bitopertin Bitopertin is an investigational, clinical-stage, orally administered inhibitor of glycine transporter 1 (GlyT1) that is designed to modulate...

VANCOUVER, British Columbia, Oct. 18, 2026 (GLOBE NEWSWIRE) — Cambria Gold Mines Inc. (TSXV: CAMB; OTCQX: CAMVF) (“Cambria” or the “Company”) is pleased to announce new assay results from the ongoing infill drilling program at the Premier Mining Complex (the “Premier Gold Project” or “PGP”), located near Stewart in northwestern British Columbia. Results from four diamond drillholes totalling 657 metres are reported herein. Highlight intervals include:98.56 g/t Au over 8.2 m (incl. 794.00 g/t Au over 1.0 m) in hole SC26-2714 22.62 g/t Au over 4.4 m (incl. 93.80 g/t Au over 1.0 m) in hole SC26-2710 3.75 g/t Au over 20.0 m (incl. 19.95 g/t Au over 1.0 m) in hole SC26-2710 4.55 g/t Au over 10.6 m and 2.32 g/t Au over 30.0 m in hole SC26-2719“High gold grades over potentially underground bulk mineable widths at the Silver Coin Deposit...

WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced presentations at United European Gastroenterology Week (UEGW) 2026 in Barcelona. The presentations include the first scientific congress presentation of clinical data across all three of Spyre’s IBD antibodies—SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23)—which are now being tested as monotherapies and pairwise combinations in the SKYLINE study, as well as new preclinical data demonstrating additive efficacy of these complementary mechanisms. “Despite significant advances...

With just three days to go, the 2026 iCAUR International User Summit will feature four core highlights under the theme “Classic Never Fades | Make It Yours”: brand launch, user co-creation, test-drive experience and ecosystem engagement. The iCAUR V25 will make its official debut at the summit, joining the V23 and V27 to further enrich the V Series lineup. The first iCAUR Customization Festival will kick off, featuring 20 customized vehicles and the launch of “User-centric Experience” global user ecosystem. The V Series Test-Drive Camp, Ecosystem Showroom, AiMOGA robot, Robotaxi products and technologies will deliver a multi-dimensional immersive experience.WUHU, China, Oct. 17, 2026 (GLOBE NEWSWIRE) — The 2026 iCAUR International User Summit will run from October 19 to 23. With just three days to go before the opening,...

ABU DHABI, United Arab Emirates, Oct. 16, 2026 (GLOBE NEWSWIRE) — NIP Group Inc. (“NIP Group” or the “Company”) (NASDAQ: NIPG), a leading digital entertainment company, today announced that the Company’s extraordinary general meeting of shareholders (the “EGM”) was held in Hong Kong on October 16, 2026. During the EGM, the following proposed resolutions were duly passed:by a special resolution that, subject to the passing of Resolution 2, the Company’s authorized share capital be increased FROM US$200,000 divided into 2,000,000,000 shares comprising (i) 1,756,459,263 Class A ordinary shares of a par value of US$0.0001 each (the “Class A Ordinary Shares”), (ii) 148,331,658 Class B1 ordinary shares of a par value of US$0.0001 each (the “Class B1 Ordinary Shares”) and (iii) 95,209,079 Class B2 ordinary shares of a par value of US$0.0001...

SAN JOSE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) — Blaize Holdings, Inc. (NASDAQ: BZAI, NASDAQ: BZAIW) (“Blaize,” the “Company,” “we,” “us,” and “our”), a leader in programmable, energy-efficient AI computing, announced today that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series B Preferred Stock, par value $0.0001 per share, for each outstanding share of Blaize common stock held of record on October 26, 2026. The outstanding shares of Series B Preferred Stock will vote together with the outstanding shares of the Company’s common stock as a single class exclusively with respect to any proposal to adopt an amendment to the Company’s certificate of incorporation to reclassify the outstanding shares of the Company’s common stock into a smaller number of shares of such common stock...

Vancouver, BC, Oct. 16, 2026 (GLOBE NEWSWIRE) — Trident Resources Corp. (TSXV: ROCK) (OTCQB: TRDTF) (Frankfurt: 6BP0) (“Trident” or the “Company”) announces that, further to its news release dated September 21, 2026 (the “Prior Release”), and at the request of the TSX Venture Exchange (the “TSXV”), it is providing updated and additional information regarding its engagement of Freedom Financial Research, LLC (“FFR”) to provide marketing and investor awareness services to the Company. This news release restates, in full, the disclosure regarding the FFR engagement contained in the Prior Release, as updated and supplemented below, and supersedes that disclosure. Background and Place of Business of FFR: FFR is a limited liability company with its principal place of business at 435 Merchant Walk Square, Suite 300-64, Charlottesville,...